$126.7M in CY2024 Part D spend175K claims · 34K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Dalfampridine used for?
Dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS).
Is there a generic for Dalfampridine?
Yes. 5 ANDAs filed at FDA, 5 generic manufacturers currently shipping.
How much does my plan pay for Dalfampridine?
Across 329 Part D plans, Dalfampridine averages $0.386/unit (NADAC). Lowest available: $0.386/unit. Highest in distribution: $0.386/unit.
Is Dalfampridine on the FDA shortage list?
No. Dalfampridine is not currently on the FDA Drug Shortage Database.
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.